SEC Form 4 · accession 0001209191-19-010285
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Roth
Officer — Chief Medical Officer
Period of report
Feb 12, 2019
Accepted (ET)
Feb 14, 2019 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 12, 2019 | A | 87,000 | $0.00 | A | 87,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $6.71 | Feb 12, 2019 | A | 75,000 | A | — | Feb 11, 2029 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock. These restricted stock units will vest in full on March 31, 2022.
- F2This option becomes exercisable as to 25% of the shares underlying the award on February 29, 2020, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.